Search

Sarepta Therapeutics and GenEdit Share Progress on Research Collaboration and Announce Agreement to Develop Gene Editing Therapeutics for Neuromuscular Diseases
A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of SRP-9001 (Delandistrogene Moxeparvovec) in Participants With Duchenne Muscular Dystrophy (DMD) (EMBARK)
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2021 Financial Results and Recent Corporate Developments on March 1, 2022
Sarepta Therapeutics Announces the Launch of SareptaCircle to Highlight the Experiences of Individuals and Families Living with Rare Disease
Sarepta Therapeutics anuncia el lanzamiento de SareptaCircle para destacar las experiencias de personas y familias que viven con enfermedades raras
Community Letter: Q1 update on LGMD programs in development
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2021 Financial Results and Recent Corporate Developments
Sarepta Therapeutics to Present at Upcoming Investor Conferences
Sarepta Therapeutics Announces Fifth Year of Route 79, The Duchenne Scholarship Program